Abstracts by keywords: DPP-4 inhibitors
According to the National Care Guideline (NVL) for the treatment of T2DM, the use of various antidiabetic therapies should be gradual if patients are unable to achieve their individual therapy goals through lifestyle changes, e.g. B. by changing your eating habits and increasing physical activity.3 Known risk factors such as previous cardiovascular and renal diseases should also be taken into account when making individual treatment decisions. The combination of metformin with an SGLT-2 inhibitor (SGLT-2i) or a GLP-1 receptor agonist (GLP-1-RA) is recommended, for example, for patients who already have clinically relevant cardiovascular disease (CVD ).4 Furthermore, dipeptidyl peptidase-4 inhibitors (DPP-4i) in addition to metformin represent another treatment alternative for lowering blood sugar, but did not show significant benefits in reducing cardiovascular events. Cardiovascular diseases cause the highest expenditure in the German healthcare system and are responsible for up to 50% of the treatment costs of patients with T2DM due to the frequently required hospital stays.5 The present healthcare research study compares the direct healthcare costs of T2DM patients who receive treatment with the SGLT -2 inhibitor empagliflozin (EMPA) started with patients treated for the first time with DPP-4i or GLP-1-RA from the perspective of the statutory health insurance in Germany.